The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
20 May 2013 | FRANCE 24
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
17 May 2013 | Eurekalert Inf Dis
The two companies that make vaccines against cervical cancer announced Thursday that they would cut their prices to the world’s poorest countries below $5 per dose, eventually making it possible for millions of girls to be protected against a major deadly cancer.
14 May 2013 | New York Times
A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine development.
10 May 2013 | Science Daily
"This trial has provided a clear, swift answer about a specific vaccine strategy. It's not the answer we hoped for, but the search doesn't end here. There are other approaches that must be pursued without delay, and this result will help to focus and guide research efforts," said Mitchell Warren, AVAC executive director.
26 April 2013 | AVAC press release
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who became infected with HIV.
25 April 2013 | National Institute of Allergy and Infectious Diseases (NIAID) press release
The US government’s goal of vaccinating young girls against the human papillomavirus has been disappointing, with less than a third of teenagers having completed a full course of HPV vaccine. But now the United States can look to Australia, which six years into a successful nationwide HPV vaccination campaign has experienced a sharp decline in the number of new cases of genital warts among young men and women.
19 April 2013 | New York Times
In what may be an important step toward a long-elusive AIDS vaccine, American researchers have minutely tracked one person’s powerful immune response to the virus to see how a series of mutations led to an antibody that can defeat many H.I.V. strains. A vaccine still remains far off, but the research lighted up one complex path that may someday be followed to that distant goal.
04 April 2013 | New York Times
For the first time, scientists have tracked in a patient the evolution of a potent immune molecule that recognizes many different HIV viruses. By revealing how these molecules — called broadly neutralizing antibodies — develop, the research could inform efforts to make vaccines that elicit similar antibodies that can protect people from becoming infected with HIV.
04 April 2013 | Nature
Their approach, which applies pioneering computational and genetic engineering techniques to create an HIV immunogen—the active ingredient of a vaccine—could have significant implications for the design of preventive vaccines against a wide variety of other pathogens as well.
29 March 2013 | IAVI